Literature DB >> 3708204

Inhibition of the myocardial Ca2+ inward current by the class 1 antiarrhythmic agent, cibenzoline.

M Holck, W Osterrieder.   

Abstract

Cibenzoline, a class 1 (local anaesthetic-type) antiarrhythmic drug, was investigated for possible effects upon the myocardial Ca2+ inward current. In voltage-clamp experiments with isolated cardiac myocytes of guinea-pig, cibenzoline caused a concentration-dependent inhibition of the Ca2+ current, with an IC50 of 14 microM. Inhibition of the Ca2+ current by cibenzoline (2 microM) was dependent upon stimulation frequency, with a greater block occurring at 2 Hz (approximately 50%) than at 0.2 Hz (approximately 15%). The magnitude of Ca2+ current block was also potential-dependent. A markedly greater inhibition by cibenzoline (20 microM) was recorded when myocytes were depolarized (to +20 mV) from a holding potential of -35 mV than of -80 mV. At the less negative potential, cibenzoline also caused a reduction in the level of the holding current, which suggests a decrease in the inwardly rectifying K+ current. Cibenzoline also caused a concentration-dependent inhibition of KCl-induced contractures of isolated aortic strips of the rat (IC50 = 55 microM) and a reduction in contractile force of isolated, electrically-stimulated papillary muscles of the guinea-pig (IC50 = 35 microM). Thus, cibenzoline possesses Ca2+ channel blocking (class 4) properties in addition to its local anaesthetic actions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3708204      PMCID: PMC1916814          DOI: 10.1111/j.1476-5381.1986.tb14588.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  Calcium-dependent action potentials produced by catecholamines in guinea pig atrial muscle fibers depolarized by potassium.

Authors:  A J Pappano
Journal:  Circ Res       Date:  1970-09       Impact factor: 17.367

2.  The electrophysiological basis of the bradycardic action of AQA 39 on the sinoatrial node.

Authors:  W Osterrieder; D Pelzer; Q F Yang; W Trautwein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-11       Impact factor: 3.000

3.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

4.  AQA 39*, a new bradycardic agent which blocks myocardial calcium (Ca) channels in a frequency- and voltage-dependent manner.

Authors:  W Trautwein; D Pelzer; T F McDonald; W Osterrieder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-11       Impact factor: 3.000

5.  Calcium channel block and recovery from block in mammalian ventricular muscle treated with organic channel inhibitors.

Authors:  D Pelzer; W Trautwein; T F McDonald
Journal:  Pflugers Arch       Date:  1982-08       Impact factor: 3.657

6.  Membrane currents in cat myocardium: separation of inward and outward components.

Authors:  T F McDonald; W Trautwein
Journal:  J Physiol       Date:  1978-01       Impact factor: 5.182

7.  Studies on the inhibitory effect of verapamil on the slow inward current in mammalian ventricular myocardium.

Authors:  M Kohlhardt; Z Mnich
Journal:  J Mol Cell Cardiol       Date:  1978-11       Impact factor: 5.000

8.  On the mechanism of slow calcium channel block in heart.

Authors:  T F McDonald; D Pelzer; W Trautwein
Journal:  Pflugers Arch       Date:  1980-05       Impact factor: 3.657

9.  Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia.

Authors:  J S Millar; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1982-03       Impact factor: 8.739

10.  Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state.

Authors:  B P Bean
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

View more
  10 in total

1.  Mid-ventricular obstruction occurred in hypertrophic left ventricle of heterozygous Fabry's disease-Favorable effects of cibenzoline: A case report.

Authors:  Shinya Nishizawa; Tomoko Osamura; Norikazu Takechi; Shigehiro Kusuoka; Keizo Furukawa
Journal:  J Cardiol Cases       Date:  2011-09-07

2.  Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Tai Sekine; Masao Daimon; Rei Hasegawa; Kiyomi Teramoto; Takayuki Kawata; Nobuhiro Tanaka; Yasuhiro Takei; Kenji Takazawa; Katsuya Yoshida; Issei Komuro
Journal:  Heart Vessels       Date:  2006-11-27       Impact factor: 2.037

3.  Effect of cibenzoline on biventricular pressure gradients in a pediatric patient with hypertrophic obstructive cardiomyopathy.

Authors:  Takamichi Ishikawa; Satoru Iwashima; Takehiko Ohzeki
Journal:  Pediatr Cardiol       Date:  2010-02-07       Impact factor: 1.655

4.  Cibenzoline, an ATP-sensitive K(+) channel blocker, binds to the K(+)-binding site from the cytoplasmic side of gastric H(+),K(+)-ATPase.

Authors:  Y Tabuchi; H Yashiro; S Hoshina; S Asano; N Takeguchi
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 5.  Pharmacological cardioversion of atrial fibrillation: current management and treatment options.

Authors:  Giuseppe Boriani; Igor Diemberger; Mauro Biffi; Cristian Martignani; Angelo Branzi
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Inhibition of the ATP-sensitive potassium channel by class I antiarrhythmic agent, cibenzoline, in rat pancreatic beta-cells.

Authors:  M Kakei; M Nakazaki; T Kamisaki; I Nagayama; Y Fukamachi; H Tanaka
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

7.  Cibenzoline inhibits diazoxide- and 2,4-dinitrophenol-activated ATP-sensitive K+ channels in guinea-pig ventricular cells.

Authors:  T Sato; B Wu; S Nakamura; T Kiyosue; M Arita
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

Review 8.  Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias.

Authors:  D W Harron; R N Brogden; D Faulds; A Fitton
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

9.  Effects of the Na+ antagonist cibenzoline on left ventricular function of postischemic hearts.

Authors:  H M Hoffmeister; M E Beyer; L Seipel
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

10.  Effects of cibenzoline, a new class Ia antiarrhythmic drug, on various membrane ionic currents and action potentials of guinea-pig ventricular cells.

Authors:  T Sato; B Wu; T Kiyosue; M Arita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.